The number of vaccines granted emergency use authorization (EUA) in the country has reached 7, according to the Food and Drug Administration (FDA).
According to FDA Director-General Eric Domingo, this includes Pfizer-Biotech, AstraZeneca, Sputnik V, Sinovac, Bharat Biotech, Janssen, and Moderna.
There is no application for the Sinopharm vaccine yet but it was granted an emergency use listing (EUL) by the World Health Organization on May 7. Domingo explained that the Department of Health may apply for an EUL for Sinopharm. He said the process will be fast due to the previous WHO EUL.
“It will not take very long, kasi kapag may ganyang EUL na from WHO, we will be able to ask WHO for the pertinent clinical trial data and for the information,” explained Domingo.
Sinopharm’s data on its effect on those aged 60 and over is limited, but the WHO has not set limits on its use in the elderly.
According to Domingo, Sinopharm’s efficacy will reach 79 percent.
“Although very similar po ito sa Sinovac, ang Sinopharm has very liited data on people 6o years ang above, however, the WHO decided not to put a cap on the age, basta 18 and above, inappprove po ito ng WHO, believing na mayroon namang kaunting data showing na it’s useful in older people,” he said.
FDA already issued EUA to 7 brands of COVID-19 vaccines
The FDA is waiting for Novavax to apply for an EUA.
Meanwhile, nearly 200,000 doses of the COVID-19 vaccines made by Pfizer and BioNTech arrived in the Philippines.
The Department of Health said three areas are expected to get the Pfizer vaccines first.
Galvez said the planned vaccination center would be able to facilitate around 10,000 individuals daily.
The Philippines seeks to vaccinate 500,000 individuals daily in the National Capital Region, and 200,000 individuals nationwide.